Back to Search Start Over

Patient-derived xenograft models capture genomic heterogeneity in endometrial cancer

Authors :
Bonazzi, Vanessa F.
Kondrashova, Olga
Smith, Deborah
Nones, Katia
Sengal, Asmerom T.
Ju, Robert
Packer, Leisl M.
Koufariotis, Lambros T.
Kazakoff, Stephen H.
Davidson, Aimee L.
Ramarao-Milne, Priya
Lakis, Vanessa
Newell, Felicity
Rogers, Rebecca
Davies, Claire
Nicklin, James
Garrett, Andrea
Chetty, Naven
Perrin, Lewis
Pearson, John V.
Patch, Ann Marie
Waddell, Nicola
Pollock, Pamela M.
Bonazzi, Vanessa F.
Kondrashova, Olga
Smith, Deborah
Nones, Katia
Sengal, Asmerom T.
Ju, Robert
Packer, Leisl M.
Koufariotis, Lambros T.
Kazakoff, Stephen H.
Davidson, Aimee L.
Ramarao-Milne, Priya
Lakis, Vanessa
Newell, Felicity
Rogers, Rebecca
Davies, Claire
Nicklin, James
Garrett, Andrea
Chetty, Naven
Perrin, Lewis
Pearson, John V.
Patch, Ann Marie
Waddell, Nicola
Pollock, Pamela M.
Source :
Genome Medicine
Publication Year :
2022

Abstract

Background: Endometrial cancer (EC) is a major gynecological cancer with increasing incidence. It comprises four molecular subtypes with differing etiology, prognoses, and responses to chemotherapy. In the future, clinical trials testing new single agents or combination therapies will be targeted to the molecular subtype most likely to respond. As pre-clinical models that faithfully represent the molecular subtypes of EC are urgently needed, we sought to develop and characterize a panel of novel EC patient-derived xenograft (PDX) models. Methods: Here, we report whole exome or whole genome sequencing of 11 PDX models and their matched primary tumor. Analysis of multiple PDX lineages and passages was performed to study tumor heterogeneity across lineages and/or passages. Based on recent reports of frequent defects in the homologous recombination (HR) pathway in EC, we assessed mutational signatures and HR deficiency scores and correlated these with in vivo responses to the PARP inhibitor (PARPi) talazoparib in six PDXs representing the copy number high/p53-mutant and mismatch-repair deficient molecular subtypes of EC. Results: PDX models were successfully generated from grade 2/3 tumors, including three uterine carcinosarcomas. The models showed similar histomorphology to the primary tumors and represented all four molecular subtypes of EC, including five mismatch-repair deficient models. The different PDX lineages showed a wide range of inter-tumor and intra-tumor heterogeneity. However, for most PDX models, one arm recapitulated the molecular landscape of the primary tumor without major genomic drift. An in vivo response to talazoparib was detected in four copy number high models. Two models (carcinosarcomas) showed a response consistent with stable disease and two models (one copy number high serous EC and another carcinosarcoma) showed significant tumor growth inhibition, albeit one consistent with progressive disease; however, all lacked the HR deficiency gen

Details

Database :
OAIster
Journal :
Genome Medicine
Notes :
application/pdf
Publication Type :
Electronic Resource
Accession number :
edsoai.on1343975980
Document Type :
Electronic Resource